Publication number: 20220274982
Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
Type:
Application
Filed:
July 28, 2020
Publication date:
September 1, 2022
Applicant:
Takeda Pharmaceutical Company Limited
Inventors:
Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI